Search Results

Expanding ketamine indications, fortifying IP, enabling earlier partnerships, and accelerating FDA pathways - underpinned by PharmaTher’s Digital Health AI division, leveraging the Company’s FDA-approved ketamine ANDA CMC and KetaVault(TM) data advantage.

Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoing

Sensorion announced a €50.5 million offering reserved to specific categories of investors through the issuance of 88,594,737 new ordinary shares of the Company at a price per New Share of €0.57 to the benefit of Redmile Group, Invus and Sofinnova Partners, existing shareholders, and leading US Healthcare Specialists funds including Aquilo Capital, as well as two large investment management firms.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the 505(b)(2) New Drug Application (NDA) approval from the U.S. Food and Drug Administration (“FDA”) for PEMRYDI RTU®.